Mattoo Aditya, Goldfarb David S
Department of Medicine, NYU School of Medicine, New York, NY, USA.
Semin Nephrol. 2008 Mar;28(2):181-91. doi: 10.1016/j.semnephrol.2008.01.011.
Cystinuria is an inherited disorder characterized by the impaired reabsorption of cystine in the proximal tubule of the nephron and the gastrointestinal epithelium. The only clinically significant manifestation is recurrent nephrolithiasis secondary to the poor solubility of cystine in urine. Although cystinuria is a relatively common disorder, it accounts for no more than 1% of all urinary tract stones. Thus far, mutations in 2 genes, SLC3A1 and SLC7A9, have been identified as being responsible for most cases of cystinuria by encoding defective subunits of the cystine transporter. With the discovery of mutated genes, the classification of patients with cystinuria has been changed from one based on phenotypes (I, II, III) to one based on the affected genes (I and non-type I; or A and B). Most often this classification can be used without gene sequencing by determining whether the affected individual's parents have abnormal urinary cystine excretion. Clinically, insoluble cystine precipitates into hexagonal crystals that can coalesce into larger, recurrent calculi. Prevention of stone formation is the primary goal of management and includes hydration, dietary restriction of salt and animal protein, urinary alkalinization, and cystine-binding thiol drugs.
胱氨酸尿症是一种遗传性疾病,其特征是肾单位近端小管和胃肠道上皮细胞对胱氨酸的重吸收受损。唯一具有临床意义的表现是由于胱氨酸在尿液中溶解度低而导致的复发性肾结石。尽管胱氨酸尿症是一种相对常见的疾病,但它在所有尿路结石中所占比例不超过1%。迄今为止,已确定2个基因SLC3A1和SLC7A9中的突变通过编码胱氨酸转运蛋白的缺陷亚基导致了大多数胱氨酸尿症病例。随着突变基因的发现,胱氨酸尿症患者的分类已从基于表型(I、II、III型)转变为基于受影响基因(I型和非I型;或A和B型)。大多数情况下,通过确定受影响个体的父母是否有异常的尿胱氨酸排泄,无需进行基因测序即可使用这种分类。临床上,不溶性胱氨酸沉淀形成六边形晶体,可聚合成更大的复发性结石。预防结石形成是治疗的主要目标,包括水化、限制盐和动物蛋白的饮食、尿液碱化以及结合胱氨酸的硫醇类药物。